OneSource Speciality Pharma announced it has received Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic� (semaglutide) in Saudi Arabia, clearing the path for commercialsing the product with Hikma Pharmaceuticals PLC (Hikma) as their exclusive commercialisation partner for the Middle East and North Africa (MENA).The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region.Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state of-the-art integrated Biologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based on sales1, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.Powered by Capital Market - Live News

Net Loss of OneSource Specialty Pharma reported to Rs 88.70 crore in the quarter ended December 2025 as against net loss of Rs 68.85 crore during the previous quarter ended December 2024. Sales declined 26.04% to Rs 290.34 crore in the quarter ended December 2025 as against Rs 392.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales290.34392.56 -26 OPM %5.9736.14 - PBDT-16.28102.78 PL PBT-85.9234.02 PL NP-88.70-68.85 -29 Powered by Capital Market - Live News

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live News

OneSource Specialty Pharma has allotted 23,000 equity shares under ESOP on 09 December 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs 11,45,62,136/- (constituting of 11,45,62,136 equity shares of Re 1/- each) to Rs 11,45,85,136/- (constituting of 11,45,85,136 equity shares of Re 1/- each). Powered by Capital Market - Live News

Net profit of OneSource Specialty Pharma reported to Rs 10.49 crore in the quarter ended September 2025 as against net loss of Rs 42.08 crore during the previous quarter ended September 2024. Sales rose 12.49% to Rs 375.76 crore in the quarter ended September 2025 as against Rs 334.05 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales375.76334.05 12 OPM %28.3423.14 - PBDT75.5736.65 106 PBT5.74-31.63 LP NP10.49-42.08 LP Powered by Capital Market - Live News